To more comprehensively assess the pathogenic contribution of the PTEN-PI3K-AKT pathway to T-cell acute lymphoblastic leukemia (T-ALL), we examined diagnostic DNA samples from children with T-ALL using array comparative genomic hybridization and sequence analysis. Alterations of PTEN, PI3K, or AKT were identified in 47.7% of 44 cases.
Introduction
Despite recent improvements in therapy, approximately 25% of children and 50% to 70% of adults with T-cell acute lymphoblastic leukemia (T-ALL) develop treatment-resistant disease, 1,2 which carries a dire prognosis. 3 Molecularly targeted agents hold considerable promise for the treatment of T-ALL, although limits in our current understanding of the key pathways that drive T-ALL pathogenesis restrict our ability to use these agents effectively.
PTEN is a negative regulator of oncogenic PI3K-AKT signaling, 4 and recent studies have demonstrated the inactivation of PTEN in human T-ALL cell lines and primary samples. [5] [6] [7] [8] Furthermore, the inactivation of PTEN has been shown to play a prominent role in resistance to NOTCH inhibition in T-ALL cell lines, an effect that appears to be mediated by AKT. 7 The activation of PI3K-AKT signaling can also occur by mutation of PI3K or AKT genes, which have not previously been assessed in T-ALL. Finally, the spectrum of PTEN mutations has not been extensively analyzed in clinical samples of primary T-ALL. Here we investigated the frequency and prognostic implications of PTEN, PI3K, and AKT abnormalities in childhood T-ALL, using array comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH), and sequence analysis.
Methods
T-ALL diagnostic specimens were collected with informed consent obtained in accordance with the Declaration of Helsinki and Institutional Review Board approval from children treated on Children's Oncology Group 9404 or Dana-Farber Cancer Institute 00-001 clinical trials. 9, 10 Complete materials and methods are available in supplemental data (available on the Blood website; see the Supplemental Materials link at the top of the online article).
Results and discussion
We performed array CGH with genomic DNAs from 47 pediatric T-ALL diagnostic specimens, 7 of which were reported previously. 5 Homozygous deletions of PTEN were identified in 2 cases (cases 44 and 45), and heterozygous deletions in 2 others (cases 34 and 16; Figure 1 ). An additional case, T-ALL 13, harbored a heterozygous deletion that spanned a locus immediately upstream of PTEN, with no CGH evidence of deletion involving PTEN coding sequence. Because this deletion may or may not have disrupted upstream gene regulatory elements, we considered the PTEN status of this case to be indeterminate. FISH analysis with a commercial PTEN probe was used to validate our CGH results in cases with sufficient cells (Figure 1B-G) . Overall, PTEN deletions were identified in 8.7% (n ϭ 4 of 46) of primary T-ALL samples.
To identify other genetic lesions that could activate PI3K-AKT signaling, we carefully examined the CGH data but did not find focal copy number alterations involving the PI3K or AKT genes, or the PDK1 and p70s6k genes, which encode other components of the pathway known to be amplified in other types of human cancers. We then sequenced the entire PTEN coding region in 44 of the 47 samples on which CGH arrays were performed, as well as selected AKT and PI3K exons known to harbor oncogenic mutations in human cancers. These included exons 9 and 20 of PIK3CA (encoding the catalytic subunit of class IA PI3K), 11, 12 exons 12 and 13 of PIK3RA (encoding the regulatory subunit of class IA PI3K), 13 and exon 2 of the AKT1-3 genes. 14 We additionally sequenced exons 1 and 2 of NRAS and KRAS and exons 3 and 13 of PTPN11, which act upstream of PI3K-AKT signaling and are each known to harbor mutations in some cases of ALL, [15] [16] [17] as well as exons 26, 27, and 34 of NOTCH1, and exons 9 and 10 of FBXW7. 18, 19 Nonsynonymous sequence alterations in PTEN were identified in 12 (27.3%) of the 44 primary T-ALL patient samples that were sequenced. Each mutation consisted of a unique nonsense or frame-shift mutation in exon 7, most of which resulted from small insertions or insertion/deletions that were predicted to cause truncation of the protein resulting from premature termination of translation. Of the 12 T-ALL cases with PTEN sequence alterations, 3 harbored biallelic alterations resulting from compound heterozygous mutations, whereas the other 9 harbored simple heterozygous mutations. No mutations were identified in cases with heterozygous PTEN deletions. Strikingly, all of the mutations identified were predicted to disrupt the PTEN protein within an 18-amino acid region of the C2 domain, leading to a carboxyterminal truncation (Figure 2A ; supplemental Table 1) . Importantly, the PTEN phosphatase core domain, encoded by exon 5 and targeted by half of the PTEN mutations described in other types of primary human tumor samples, 20 was not disrupted by mutations identified in our T-ALL samples. Although PTEN mutations can occur in exon 7 in other cancers, including glioblastoma, endometrial, breast, and prostate carcinomas, 20 detection of mutations exclusively in this region has not been described in other types of human cancer. [20] [21] [22] Interestingly, the clustering of mutations within exon 7 is specific to primary T-ALL samples, as PTEN mutations in T-ALL cell lines frequently disrupt the phosphatase domain. 5, 7, 23 Nonsynonymous sequence alterations were also identified in the PI3K and AKT genes (supplemental Table 1 ). An E17K AKT1 activating mutation was identified in one case, whereas 2 others harbored activating mutations of PIK3CA, encoding the catalytic subunit of class IA PI3K. Two additional cases harbored novel in-frame insertions/deletions in the PI3K regulatory subunit PIK3R1, in a region of the gene frequently mutated in human cancers. 13, 24 Alterations of PTEN, AKT, and PI3K were mutually exclusive and occurred in 21 (47.7%) of the 44 primary T-ALL patient samples analyzed by both array CGH and sequencing ( Figure 2B ). When analyzed together, genetic alterations in the PTEN-PI3K-AKT pathway did not predict event-free survival ( Figure 2C ), in contrast to PTEN deletions, which were significantly associated with early treatment failure ( Figure 2D ). and Genus acquisition software version 3.92 build 7 (Genetix USA). Note that the Genus cytogenetic image acquisition software applies an automated "thresholding" algorithm that sets a signal intensity threshold below which any signal is considered background and thus excluded from the final composite image. During image acquisition, all images generated by the software were compared to the view from the microscope to confirm that they were fully representative. the 4 patients with PTEN deletions, including both cases with homozygous deletions, compared with none of the 12 cases with PTEN exon 7 mutations (P ϭ .007). Nevertheless, the number of patients with PTEN deletions we have identified is small, and it will be important to confirm the prognostic utility of PTEN deletions in a sufficient number of additional cases before incorporating this finding into clinical decision-making. We also identified activating mutations of NRAS in 4 cases, including 3 without genetic alterations in the PTEN-PI3K-AKT pathway and one with a PTEN mutation ( Figure 2B ). One of these cases harbored a heterozygous NF1 deletion (supplemental Table  1 ). An activating KRAS mutation was identified in a case that also had an activating NRAS mutation. There was no apparent correlation between alterations of the PTEN-PI3K-AKT or RAS-NF1 pathways and known T-ALL oncogenic abnormalities, including NOTCH1 or FBXW7 mutation, MYB duplication, or CDKN2A gene deletion (supplemental Table 1 ). Finally, 2 cases had a homozygous RB1 deletion (supplemental Table 1 ), a genomic aberration not previously described in primary T-ALL samples.
The detection of abnormalities in the PTEN, PI3K, and AKT genes in a large fraction of primary T-ALL samples demonstrates a prominent role for oncogenic PI3K-AKT signaling in the pathogenesis of T-ALL. Moreover, PTEN deletions appeared to impart a high risk of induction failure with contemporary chemotherapy. Our findings add significant support to the rationale for clinical trials of small molecule inhibitors of PI3K, AKT, and mTOR, now in development, 25 as therapeutic agents for T-ALL. Figure 1 identified nonsynonymous sequence alterations in 12 of these samples, all of which were predicted to disrupt the PTEN protein within an 18-amino acid region of the C2 domain. Note that the specific mutations in cases 14 and 27 were impossible to determine because of the presence of 2 simultaneous frameshift sequences. (B) Targeted sequencing of PIK3R1, PIK3CA, and AKT1-3 exons known to be mutated in human cancer identified nonsynonymous sequence alterations in PTEN and the PI3K-AKT pathway in 47.7% of primary T-ALL cases. Lesions within the PTEN-PI3K-AKT pathway were mutually exclusive. Abnormalities in the NF1 and RAS genes were also identified but were not solely associated with PTEN-PI3K-AKT pathway abnormalities. *Novel in-frame insertion/deletions. (C-D) Kaplan-Meier event-free survival curves for the 44 cases analyzed by CGH and sequencing demonstrate that, overall, genetic alterations of the PTEN-PI3K-AKT pathway did not predict event-free survival, whereas deletions of PTEN were significantly associated with early treatment failure.
